Byotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations.

CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings.

CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.